Overview
This is a randomized, open, single-dose, crossover-design, phase I study to evaluate the safety and pharmacokinetics after co-administration of CTL0201 and CTL0202 or administration of CT-L02 in healthy volunteers.
Eligibility
Inclusion Criteria:
- Healthy participant aged 19 to 55 years, at screening
- A participant who has a body mass index (BMI) of 18.0~29.9 kg/m2, at screening
- A participant who is judged to be eligible to participate by the results of screening tests (vital signs, clinical laboratory tests, 12-lead ECG, etc.) by the principal investigator
Exclusion Criteria:
- A participant who has taken drugs that induce or inhibit drug metabolizing enzymes
- A participant who has participated in other clinical trials or bioequivalence studies within 6 months prior to the first dose of the investigational drug
- A participant who has a history of gastrointestinal surgery that may affect drug absorption
